EUVIMEDEUVIMED entdecken
Crossref

Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer

Elaheh Hassani, Sahand Mozzendizaji, Vahid Shafiei-Irannejad, Adel Mohammadzadeh

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03764-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Elaheh Hassani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran. Hauptthemen laut MEDLINE: Metformin, Doxorubicin, CD8-Positive T-Lymphocytes, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Breast cancer is a leading cause of cancer-related deaths among women worldwide. The presence and function of CD8 + T cells in the tumor microenvironment have been associated with better patient outcomes. Drug toxicity has posed a significant challenge to the clinical implementation of chemotherapy-based strategies in cancer treatment. METHODS: In this study, we employed flow cytometry to investigate the potential synergistic immunomodulatory effects on CD8 + T cells in a mouse model of breast cancer by combining metformin, an anti-diabetic medication, with doxorubicin. RESULTS: Through flow cytometry analysis, we observed that the combination of the two drugs led to an increased percentage of CD8 + T cells compared to either drug alone. The modulation of HIF-1α and STAT3 gene expression in the combination group further confirmed the efficacy of this approach. CONCLUSIONS: Our findings suggest that combining metformin with doxorubicin can enhance the anticancer activity of doxorubicin and decrease its cytotoxicity in a 4T1 breast cancer mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDoxorubicinCD8-Positive T-LymphocytesMammary Neoplasms, ExperimentalAntibiotics, AntineoplasticBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAnimalsFemaleMiceMice, Inbred BALB CDrug SynergismHypoxia-Inducible Factor 1, alpha SubunitSTAT3 Transcription FactorCell Line, TumorFlow Cytometry

Stichwörter der Autor:innen

Breast cancerCD8 + T cellsCombination therapyDoxorubicinMetformin

Substanzen

MetforminDoxorubicinAntibiotics, AntineoplasticHypoxia-Inducible Factor 1, alpha SubunitSTAT3 Transcription FactorHif1a protein, mouseStat3 protein, mouse

Autor:innen und Institutionen

  • Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
  • Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
  • Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran. a.mohimm@gmail.com.
  • Department of Immunology and Genetics, Urmia University of Medical Sciences, Urmia, Iran. a.mohimm@gmail.com.

Zitieren

APA

Hassani, E., Mozzendizaji, S., Shafiei-Irannejad, V., & Mohammadzadeh, A. (2024). Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03764-2

Vancouver

Hassani E, Mozzendizaji S, Shafiei-Irannejad V, Mohammadzadeh A. Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03764-2

BibTeX
@article{Hassani2024,
  author = {Hassani, Elaheh and Mozzendizaji, Sahand and Shafiei-Irannejad, Vahid and Mohammadzadeh, Adel},
  title = {Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03764-2}
}
Kostenlos starten →